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Abstract
Background: The signal of an association between vaccination in the second year of life with a hexavalent vaccine and
sudden unexpected deaths (SUD) in the two days following vaccination was reported in Germany in 2003. A study to
establish whether the immunisation with hexavalent vaccines increased the short term risk of SUD in infants was conducted
in Italy.
Methodology/Principal Findings: The reference population comprises around 3 million infants vaccinated in Italy in the
study period 1999–2004 (1.5 million received hexavalent vaccines). Events of SUD in infants aged 1–23 months were
identified through the death certificates. Vaccination history was retrieved from immunisation registries. Association
between immunisation and death was assessed adopting a case series design focusing on the risk periods 0–1, 0–7, and 0–
14 days after immunisation. Among the 604 infants who died of SUD, 244 (40%) had received at least one vaccination. Four
deaths occurred within two days from vaccination with the hexavalent vaccines (RR=1.5; 95% CI 0.6 to 4.2). The RRs for the
risk periods 0–7 and 0–14 were 2.0 (95% CI 1.2 to 3.5) and 1.5 (95% CI 0.9 to 2.4). The increased risk was limited to the first
dose (RR=2.2; 95% CI 1.1 to 4.4), whereas no increase was observed for the second and third doses combined.
Conclusions: The RRs of SUD for any vaccines and any risk periods, even when greater than 1, were almost an order of
magnitude lower than the estimates in Germany. The limited increase in RRs found in Italy appears confined to the first dose
and may be partly explained by a residual uncontrolled confounding effect of age.
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Introduction
Most deaths occurring during the first two years of life are
attributable to defined causes, mainly represented by congenital
malformations, malignancies, and accidents. The events in otherwise
apparently healthy subjects, without any evident cause for the death,
are classified as SIDS (Sudden Infant Death Syndrome) during the
first year of life and SUD (Sudden Unexpected Deaths) at older ages.
During the first years of life, children receive several immunisa-
tions and some events of SIDS-SUD (in the following SUD) may
occur in temporal association with vaccination. The association
between vaccinations and SUD has been frequently investigated,
and most of the epidemiological studies rejected any causal
relationship suggested by spontaneous reports [1–12].
In 2003 the suspicion of a possible association between the
immunisation with a hexavalent vaccine (Hexavac) and the occurrence
of SUD was raised in Germany [13]. The signal was based on the
observation of three deaths occurring between November 2000 and
June 2003 in toddlers in their second year of life within 48 hours
following the administration of the fourth dose. No signal was detected
for vaccinations administered during the first year of life.
Two hexavalent products were licensed in the European Union
through a centralised licensure procedure in the year 2000: Hexavac
(by Aventis Pasteur MSD) and Infanrix hexa (by Glaxo SmithKline
Biologicals). These combined vaccines contained antigens to immunise
against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and
haemophilus influenzae type b. Since licensure the two vaccines were
extensively used in some EU countries (e.g., Germany, Italy, Austria).
Italy represented the second largest market of Hexavac in the
world and no signal of a possible association with the occurrence of
SUD emerged from the Italian pharmacovigilance reporting
system. Childhood vaccination schedules differed slightly between
Germany and Italy as four administrations were recommended in
Germany (at the 2
nd,3
rd,4
th, and between the 11
th and 15
th
months of life) and three in Italy (at the 3
rd,5
th, and 11
th-12
th
months of life). Despite these differences, it was deemed necessary
to carry out further investigations and a study protocol was agreed
with the CHMP-EMA (Committee for Medicinal Products for
Human Use – European Medicines Agency). The study was
carried out on the entire Italian population of newborns over a five
year period (1999–2003) and a report was presented in 2005 at the
CHMP-EMA.
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2004 we subsequently decided, with the intent to increase the
power of the study, to extend the observation period and to
include all infants immunised in 2004. As for the preliminary
study, the main aim was to assess whether immunisation with
hexavalent vaccines in the first two years of life was associated with
higher short term risk of unexplained death in the Italian setting.
We are now reporting the final findings of the study for the entire
period 1999–2004.
Methods
Ethics Statement
The study protocol was approved by the Ethical Committee of
the National Institute of Health with the recommendation of
avoiding direct contacts with the families of the study subjects. The
study was conducted according to the Italian law on confidenti-
ality.
Population
Around 530,000 children are born each year in Italy out of a
population of approximately 57 million inhabitants. In 2001 the
infant mortality rate was 4.7 per 1,000 newborn; the mortality rate
in second year of life was 0.3 per 1,000 infants. As in most
developed countries, mortality rates decreased during the study
period (1999–2004), as part of a long term trend [14].
The reference population was the entire population of children
who were resident in Italy. The study population consisted of all
children who died of SUD between 31 and 729 days of age in the
years 1999–2004.
Study design
Given the universal offer of infant immunisation in Italy, the
entire population was expected to be vaccinated and the limited
proportion of unvaccinated subjects might not be comparable to
the immunised population. To avoid this limitation, a study design
only based on case-subjects, according to the case-series
methodology proposed by Farrington, was adopted [15–19].
The entire information was provided by cases and each subject
also acted as his/her own control: the observation period was
arbitrarily divided into pre-defined risk period (the days immedi-
ately following the vaccination) and control period (the remaining
observation period). Each event was classified as exposed if it
occurred during the risk period and not-exposed if it occurred in
the control period. Incidence rates in the risk period were
compared with the incidence rate in the control period to obtain
an estimate of the Rate Ratio (RR). Case series design specifically
applies to the investigation of the association between exposures
that carry a transient effect and the occurrence of acute events. In
these situations the information derived by cases may provide an
unbiased estimate of the rate ratios of a hypothetical cohort study
conducted in the same source population.
Identification of cases
For each death occurring in Italy a death certificate has to be
filled in by a physician. Death certificates are collected at national
level by ISTAT (the Italian National Institute of Statistics). For the
present study, the ISTAT national database was used to retrieve
death certificates of infants aged 31–729 days from 1 January 1999
to 31 December 2004.
Certificates reporting one of the following causes of death
(classified according to the Ninth Revision of International
Classification of Diseases - ICD IX) were selected to identify the
study subjects: SIDS (ICD IX: 7980); symptoms, signs, and ill-
defined conditions (other than SIDS) (ICD IX: 780-797, and 799)
without mention of concomitant conditions (e.g., septic shock,
congenital malformations, accident); cardiac arrest (ICD IX: 4275)
without mention of congenital malformation; and foreign body in
larynx (ICD IX: 9331) without identification of the foreign body
causing the asphyxia or suffocation, or of concomitant conditions
(e.g., congenital diseases).
All individual records of death, with the text description of the
causes and of concomitant diseases or conditions, were reviewed.
Potential errors in the selection of the main cause of death and/or
in the coding process were identified. The outcome of the review
process was either to confirm the inclusion or to exclude the
subject when an identified cause of death had been reported.
Moreover, the review allowed the inclusion of additional subjects
when the cause of death was judged to be compatible with SUD
(even though the ICD-IX code was different). For instance, we
included subjects whose cause of death mentioned ‘‘sudden death’’
either alone or in combination with other ill-defined causes such as
‘‘cardiac arrest’’ or ‘‘asphyxia’’. The process was carried out by the
authors (GT, SSA, LPC, and MCDA) and in case of doubt a
consensus was reached on the basis of collective discussion. The
review process, even though not anticipated in the study protocol,
was agreed with the Scientific Committee of the study. Both
inclusion and exclusion decisions were adopted before collecting
individual vaccination histories.
The following demographic characteristics were abstracted
from the death certificates: sex, date of birth, date of death,
mothers’ citizenship, municipality of residence. Confirmation by
autopsy was not required for the eligibility of study subjects since
the results of autopsy even when requested, were not included in
the death certificate.
Vaccination histories
In Italy, immunisations included in the national program are
offered free of charge and delivered by Local Health Units
(LHUs). Different commercial products may be in use at the same
time within the National Health Service (NHS). National
vaccination surveys indicated that around 95% of newborns
complete the recommended vaccination course by the end of the
second year, and that around 95% of the vaccinations are
administered in the LHUs [20]. Parents may also ask the family
paediatrician to administer the vaccine (which in this case is paid
out of pocket by parents). In these occasions, family paediatricians
are required to communicate with the LHUs to keep the
vaccination records updated.
The Italian infant immunisation schedule includes three doses
of vaccines against diphtheria, tetanus, pertussis, poliomyelitis,
hepatitis B and haemophilus influenzae type b, to be administered
in the first year of life (at the 3
rd,5
th, and 11
th-12
th months of age);
the first MMR vaccination is recommended between the 12
th and
15
th months. During the six year study period, combined vaccines
have largely replaced the use of single antigens concomitantly
administered. Hexavalent vaccines reached 96% of the doses
administered in the first year of life in 2004 [21].
For each case the immunisation history was requested to the
competent LHU. The following data were obtained: date(s) of
immunisation, product(s), and batch number.
Statistical analyses
The observation period (31–729 days) was divided into periods
at risk (the days immediately following the vaccination) and control
period (the remaining observation period until subsequent
vaccination or death). According to the German signal and the
acute onset hypothesis, three different risk periods were considered
Sudden Unexpected Deaths and Vaccinations
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days); up to 7 days following vaccination (0–7 days); up to the end
of the second week following the vaccination (0–14 days). For the
calculation of person time, the day of vaccine administration
(index day) was considered as an entire day of exposure. Risks of
SUD in each of the three periods following vaccination were
compared with those in the control period.
RRs were estimated for the following categories of exposure:
Hexavalent products (Hexavac; Infanrix hexa); Other concomitant
administration of six antigens (e.g., pentavalent + monovalent
vaccines); Other vaccine administration (any other administration
of antigens: e.g., pentavalent vaccines; tetravalent + monovalent
vaccines; tetravalent vaccines; MMR).
Since each case acted as his/her own control, the case-series
method inherently took into account confounding factors that did
not vary with time over the observation period (such as variables
related to genetics, socio-economic status, gender, individual
frailty, presence of underlying diseases). To take into account time-
dependent confounding variables, such as age in the present study,
the observation period of each subject was subdivided not only by
risk categories (i.e., risk and control periods) but also by age classes.
RR estimates were adjusted for the following age groups: 31–80;
81–100; 101–120; 121–180; 181–360; 361–729 days.
For estimating the association between vaccination and SUD
two different analyses were carried out.
The first analysis was based on the method developed by
Farrington for self-controlled case series data (SCCS). Originally
designed to analyse the association between vaccinations and
recurrent events [15–18], the method was adapted to take into
account also terminal events, as deaths, where the observation
period is truncated (case series for censored, perturbed or curtailed
post-event exposures) [19]. All cases of SUD (vaccinated and
unvaccinated) were included in the analysis. The observation
period for each case lasted between 31 days of age and the end of
the observation period (729 days) (Figure 1A). RRs and 95%
Confidence Intervals (95% CIs) were estimated applying a specific
routine developed for the analysis of SCCS for censoring,
perturbed or curtailed post-event exposures [22]. The SCCS
method provides an overall estimate of the effect of vaccination
(including the effect of different doses), whereas limitations are
present in trying to estimate the RR of specific vaccines when
different products are administered to the same child.
The second analysis was carried out to provide risk estimates for
each vaccine (and categories of vaccines), taking into account that
children could be exposed to different types of products.
Differently from the previous analysis, only immunised children
were included and each case contributed to the observation period
from the day of the first vaccination to death (Figure 1B). The
association between specific vaccinations and deaths was investi-
gated using the Poisson regression model. The effect of age, sex,
citizenship, and calendar year was considered. In the final model,
only age, grouped in the same classes previously indicated, was
included since the other variables did not modify the estimates.
Both analyses were performed with Stata Statistical Software,
release 10 [23].
Organisation of the study
The study was coordinated by the National Centre for Epidemi-
ology, Surveillance and Health Promotion of the Italian National
Institute of Health, in collaboration with ISTAT (Italian National
Institute of Statistics) and Regional Health Authorities. A Scientific
Committee was appointed to supervise the overall activity.
Figure 1. Description of the observation period for a hypothetical subject included in the study. Legend A. Self-controlled case-series
method for censoring, perturbed or curtailed post-event exposures [19] Legend B. Poisson regression model.
doi:10.1371/journal.pone.0016363.g001
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During the six years of the study period, 4,638 deaths occurred
in Italy between 31 and 729 days of age. The ICD-IX codes of
interest were reported in the death certificates of 599 subjects (one
subject was subsequently excluded because the date of birth was
unknown). After reviewing the description of all individual causes
of death, 49 subjects originally classified with the ICD-IX codes of
interest were excluded (e.g., as a consequence of concomitant
reporting of septic shock or accident), whereas 55 subjects
originally classified with other ICD-IX codes were added
(Figure 2). The study population thus comprised 604 subjects
whose death certificate was compatible with a diagnosis of SUD.
The proportion of subjects included in the study (12.8%) was
stable in each of the six years (range 11.3%–14.3%).
The age distribution of the 604 events of SUD included in the
study clearly indicates the strong decrease in the occurrence of
SUD with age, with a decline that is particularly pronounced
around the age between the first and second vaccine dose
(Figure 3).
The median age at death of the identified subjects was 107 days,
with a greater proportion of males (male to female ratio: 1.5). The
most frequently reported cause of death was ‘‘SIDS’’ (25%),
followed by ‘‘cardiac arrest’’ (21%), and by ‘‘Foreign body in
larynx’’ (11%) (Table 1).
Out of the 604 infants, 244 (40%) had at least one recorded
vaccination (Table 1). The likelihood of vaccination increased with
age, from 5.0% under 80 days to 75.0% over 180 days. Non-
Italian citizens and children living in southern Italy had a
significantly lower probability of having the vaccination record
retrieved. Almost half of the vaccinated infants (48.4%) had
received only one vaccine dose, 34.4% two doses, and the
remaining infants received at least three doses. The median age at
each vaccine dose was consistent with the Italian immunisation
schedule (Table 2).
Figure 4 reports the distribution of immunised subjects by
interval between date of vaccination and date of death (during the
45 days following vaccination). Overall 8 children died on the
same day of vaccination or during the following day. The age
adjusted RR, estimated adopting the SCCS method for truncated
observation periods (Table 3), was 1.2; 95% CI 0.4 to 2.1 (if not
otherwise specified all RRs presented in the text are adjusted by
age). RR for any vaccination in the time window 0–7 days was 1.3
(95% CI 0.9 to 1.9) and for the 0–14 days was 1.1 (95% CI 0.8 to
1.5). In the analysis by dose, a statistically significant RR was
reached for the first dose in the risk period 0–7 days following any
vaccination (RR=1.5; 95% CI 1.0 to 2.3).
Similar estimates for the exposure to any vaccines were
obtained when the Poisson regression model was applied
(Table 4). With regard to the three main groups of vaccines
(‘‘Hexavalent products’’, ‘‘Other concomitant administration of six
antigens’’, and ‘‘Any other administration of antigens’’) the
estimates of the RRs were slightly greater than one for the
categories of ‘‘Hexavalent products’’ and ‘‘Other concomitant
administration of six antigens’’. Specifically, the RRs for the
‘‘Hexavalent products’’ were 1.5 (95% CI 0.6 to 4.2), 2.0 (95% CI
1.2 to 3.5) and 1.5 (95% CI 0.9 to 2.4), respectively for the risk
periods 0–1, 0–7 and 0–14. The risk estimates for the ‘‘Other
Figure 2. Selection of the study population, age 31–729 days, Italy 1999–2004. Legend. *One subject was excluded because the date of
birth was unknown.
doi:10.1371/journal.pone.0016363.g002
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ping with those of ‘‘Hexavalent products’’. The RRs for ‘‘Other
vaccine administration’’ were lower than 1 for any of the three
periods at risk.
The RR estimates of the two ‘‘Hexavalent products’’ (Hexavac
and Infanrix hexa) differed according to the time window at risk
considered in the analysis. Among subjects immunised with
Hexavac, one death occurred in the day of vaccination or in the
following day (RR=0.7; 95% CI 0.1 to 5.5); 12 deaths in the risk
period 0–7 (RR=2.8; 95% CI 1.4 to 5.3); and 13 deaths
(RR=1.6; 95% CI 0.8 to 3.1) for the risk period 0–14. Among
infants who received Infanrix hexa the RR ranged from 2.3 (95%
CI 0.8 to 7.7) for the first 2 days, to 1.4 (95% CI 0.6 to 3.1) for the
first week, to 1.5 (95% CI 0.8 to 2.7) for the two week risk period.
The analysis by dose for the combination of six antigens
indicated that the increase in the rate ratio was confined to the first
dose: the rate ratio for the two ‘‘Hexavalent products’’ was 2.2
(95% CI 1.1 to 4.4) in association with the first dose, and 1.0 (95%
CI 0.5 to 2.1) for the second and third dose combined (Table 5). A
similar pattern was observed for the two hexavalent products.
Three deaths occurred during the risk period 0–14 days after
the administration of the third dose: 1 day after the administration
of Hexavac (male, age 346 days); 7 days after the concomitant
administration of five antigens (male, age 385 days) and 7 days
after Infanrix hexa concomitantly administered with the first dose
of pneumococcal vaccine (female, age 428 days). A further event
occurred 12 days after the first dose of MMR (male, age 494 days).
Discussion
Our study was motivated by the safety concern that was raised
in Germany with regard to Hexavac [13] and by the magnitude of
the population exposed to the same vaccine in Italy. In Germany
between November 2000 and June 2003, three deaths had
occurred in toddlers in the second year of life within the 48 hours
following the administration of the fourth dose, out of around 1.3
million doses. The observed vs expected ratio gave an SMR
(Standardised Mortality Ratio) of around 23. The signal was
restricted to the fourth dose, whereas no signal was reported for
the three doses administered in the first year of life.
The findings of our study do not reproduce the signal. The rate
ratio observed in the Italian study, for any vaccine and for any risk
period, even when greater than 1, were almost an order of magnitude
lower than the SMR estimated in the Germany. Statistically
significant RRs were observed for hexavalent products and in
particular for Hexavac, but only in the first seven days following
vaccination. Moreover differently from the signal in Germany, the
highest RR estimate in our data is limited to the first vaccine dose, at
an age when the incidence of SUD is also the highest.
The incidence of SUD decreases around the age corresponding to
the administration of the first dose. As a consequence, the comparison
between risk periods (days closer to the vaccine shot) and control
periods (more distant days) is influenced by the decreasing trend of
the basal rates of SUD. Thus, our RRs may be at least partly affected
by the residual uncontrolled confounding effect of age.
With regard to the hexavalent products, the difference in the
risk estimates between Hexavac and Infanrix hexa is due to the
uneven distribution of events in the two weeks following
vaccination, whereas the total number of cases and person days
is similar: 13 cases and 1075 person days for Hexavac and 12 cases
and 1138 person days for Infanrix hexa. For ‘‘Other concomitant
administration of six antigens’’ the rate ratio estimates in the risk
period 0–14 days are also similar to the estimates of the two
Figure 3. Distribution of the 604 events of SUD included in the study by age of death. Legend. The three arrows indicate the median age
at first, second and third vaccine dose.
doi:10.1371/journal.pone.0016363.g003
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ratio estimates are slightly lower than 1 over any of the risk
periods. However, it should be considered that this category
concerns a heterogeneous groups of vaccines and a small number
of events.
The results of a preliminary study relevant to the years 1999–
2003 were made available and discussed at the CHMP-EMA in
April 2005. After reviewing the overall available evidence the
CHMP-EMA concluded that the benefit-risk balance for Hexavac
remained positive and no further regulatory actions were
considered to be necessary. In the same year, however, a potential
risk associated with a decreased immunogenicity of the hepatitis B
component of Hexavac was identified, and the suspension of the
marketing authorisation of this vaccine was recommended in Europe
Table 1. Characteristics of the study population and immunisation status.
All subjects (N. 604) Immunised subjects (N. 244)
NN %
Age at death (days)
31–80 218 11 5.0
81–100 65 22 33.8
101–120 52 22 42.3
121–180 109 69 63.3
181–360 93 69 74.2
361–729 67 51 76.1
Sex
Male 360 137 38.1
Female 244 107 43.9
Mother’s citizenship
1
Italian 488 206 42.2
Non-Italian 109 34 31.2
Cause of death
SIDS 151 52 34.4
Cardiac arrest 124 55 44.4
Foreign body in larynx 68 23 33.8
Symptoms, signs, and ill-defined conditions (with exclusion of SIDS) 212 95 44.8
Others
2 49 19 38.8
Year of death
1999–2000 241 84 34.9
2001–2002 194 79 40.7
2003–2004 169 81 47.9
Regional area of residence
North 252 122 48.4
Centre 88 23 26.1
South and Islands 264 99 37.5
SIDS: Sudden Infant Death Syndrome.
1The information on citizenship was missing for 7 infants.
2Causes of death judged to be compatible with sudden unexpected death after the revision of death certificates.
doi:10.1371/journal.pone.0016363.t001
Table 2. Distribution of the 244 immunised subjects by vaccine dose.
Vaccine dose Number of subjects % Median age at last dose (days) Median age at death (days)
1 118 48.4 90 125
2 84 34.4 139 220
3 31 12.7 338 422
3+MMR 11 4.5 479 552
Total 244 100.0 129 178
MMR: measles-mumps-rubella vaccine.
doi:10.1371/journal.pone.0016363.t002
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Hexavac was consequently included in the present study.
The main strength of our findings is that the study was carried
out on the entire Italian population: around 95% of 3.2 million
newborns over a six year study period were immunised in the first
two years of life. During the period 2001–2004 around 4.5 million
doses of Hexavac and Infanrix hexa, equally shared between the
two products (and presumably between the three doses), were
administered to Italian infants.
Several potential limitations should also be discussed. The
mortality rate of SUD was extremely low even after reviewing the
individual causes of death to enhance the sensitivity of case
detection: around 17 per 100,000 newborns in the first year of life
(corresponding to 538 eligible subjects), and 2 per 100,000 infants
in the second year (corresponding to 67 eligible subjects).
The identification of SUD cases based on death certificates and
not on autopsy referrals could be a limitation of the study as it may
have led to the inclusion of subjects with a defined cause of death
(not reported in the certificate). Also the revision of the death
certificates did not allow to estimate the proportion of events in
which the reported causes of death were based on the autopsy
findings. Clearly, had the autopsy been conducted on all potential
cases of SUD, further cases would have been excluded and the
estimate of the mortality rate would have been even lower. The
inclusion criteria inevitably required to be adapted to the
retrospective design. In this respect, our study subjects differed
from the case definition agreed by the Brighton collaboration,
which was specifically developed for unexplained sudden death as
an adverse event following immunisation [25]. However, the study
population may be considered more representative of the events
reported to the pharmacovigilance systems, given that spontane-
ous reporting does not require the autopsy confirmation.
Fifty-one of the 244 immunised cases (21%) were in their second
year of life, and 42 (17%) had received the third dose. Thus, in the
second year of life, or around the age when the third dose is
administered in Italy (11–12 months), the statistical power of the
study was probably low to rule out a small increase in the risk for
any specific product. Nevertheless, the fact that, despite a broader
Figure 4. Distribution of immunised subjects by interval between date of vaccination and date of death. * Legend. *Only events
occurring within 45 days from vaccination are shown.
doi:10.1371/journal.pone.0016363.g004
Table 3. Rate ratio of sudden unexpected deaths in infants of age 31–729 days by risk period (following any vaccination) and
dose, Italy 1999–2004.
Risk period: 0–1 days Risk period: 0–7 days Risk period: 0–14 days
N RR adj
1 (95% CI) N RR adj
1 (95% CI) N RR adj
1 (95% CI)
All doses 8 1.2 (0.4–2.1) 34 1.3 (0.9–1.9) 52 1.1 (0.8–1.5)
1
st dose 5 1.2 (0.4–2.5) 24 1.5 (1.0–2.3) 34 1.2 (0.8–1.6)
2
nd –3
rd dose 3 1.2 (0.3–3.0) 10 1.0 (0.4–1.9) 18 1.0 (0.6–1.6)
N: Number of deaths; RR adj: adjusted Rate Ratio; CI: Confidence Interval.
1RRs are estimated according to the self controlled case-series method for censoring, perturbed or curtailed post-event exposures [19] and adjusted by age group (31–
80; 81–100; 101–120; 121–180; 181–360; 361–729).
doi:10.1371/journal.pone.0016363.t003
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with the third dose (1 and 7 days respectively after Hexavac, and
Infanrix hexa in association with a pneumococcal vaccine, had
been administered) in around 1.5 million infants who received the
third dose of these products, represents in itself an information on
the safety of vaccines.
The retrieval of immunisation status is unlikely to have biased
our estimates. Vaccination history was ascertained on official
records after the inclusion of cases. The likelihood that we may
have missed vaccination histories of some cases may have reduced
the power of the study. However, the 95% vaccination coverage
observed in the general population is not directly relevant to our
study since we only considered a subgroup of children who died at
early age (the median age of the 604 eligible subjects was 107
days). For instance, 218 subjects had died between 31 and 80 days,
when the likelihood of being vaccinated in the corresponding
general population is negligible (given that the first dose is
recommended around 90 days).
The fact that the proportion of vaccinated infants reached a
maximum of around 75%, which is still 20% lower than the
general population coverage, is not unexpected. For example, in a
study carried out in the UK, out of 363 children, an interview was
conducted for 325 (90%), immunisation details were available for
303 (93%), and the immunisation programme had begun for 149
(49%). These immunised children represented 41% of the eligible
population, even though an accelerated schedule (at 2, 3, and 4
months) had been introduced [26].
A lower immunisation rate among SUD cases than among
controls was observed in most of the studies conducted to date
[3,5,6,10,11,26], and an explanation based on the ‘‘healthy
vaccinee effect’’ has been proposed [27]. If a child is affected by
a condition associated both to the occurrence of SUD and to the
avoidance or postponing of vaccination, the comparisons between
immunised and not immunised subjects (carried out either in
cohort or case-control studies) would be confounded and RRs
underestimated. Study design in which only cases are enrolled
have been proposed to address the problem of confounding related
to the avoidance of vaccination [15–19].
A final issue concerns the potential implications of the study
findings on the benefit-risk profile of hexavalent vaccines. The
acceptance of even weak and uncertain associations with severe
events is largely influenced by the incidence of the diseases
targeted by the vaccines, which modifies the perception of the
expected benefits. Effective vaccination campaigns, which succeed
Table 4. Rate ratio of sudden unexpected deaths in infants of age 31–729 days by risk period and type of vaccine, Italy 1999–2004.
Vaccine groups Risk period: 0–1 days Risk period: 0–7 days Risk period: 0–14 days
NP - d
RR adj
1 (95%
CI) N P-d
RR adj
1 (95%
CI) N P-d
RR adj
1 (95%
CI)
Any vaccine 8 864 1.1 (0.5–2.4) 34 3355 1.4 (0.9–2.1) 52 6104 1.1 (0.8–1.6)
All concomitant administration of six antigens 7 593 1.5 (0.7–3.5) 30 2276 1.8 (1.1–2.8) 44 4112 1.5 (1.0–2.2)
Hexavalent products
2 4 322 1.5 (0.6–4.2) 18 1231 2.0 (1.2–3.5) 25 2228 1.5 (0.9–2.4)
Hexavac 1 160 0.7 (0.1–5.5) 12 599 2.8 (1.4–5.3) 13 1075 1.6 (0.8–3.1)
Infanrix hexa 3 160 2.3 (0.8–7.7) 6 624 1.4 (0.6–3.1) 12 1138 1.5 (0.8–2.7)
Other concomitant administration of six antigens 3 271 1.4 (0.4–4.8) 12 1045 1.6 (0.8–3.0) 19 1884 1.4 (0.8–2.3)
Others 1 271 0.5 (0.1–3.4) 4 1079 0.5 (0.2–1.4) 8 1978 0.6 (0.3–1.1)
Control period 192 29875 1 192 29875 1 192 29875 1
N: Number of deaths; P-d: Person-days at risk; RR adj: adjusted Rate Ratio; CI: Confidence Interval.
1RRs are estimated by the Poisson regression model and adjusted by age group (31–80; 81–100; 101–120; 121–180; 181–360; 361–729).
2The information of the brand name of the hexavalent product was missing for 1 infant (the event occurred in the control period).
doi:10.1371/journal.pone.0016363.t004
Table 5. Rate ratio of sudden unexpected deaths in infants of age 31–729 days for the risk period 0–14 days following vaccination
with a combination of six antigens by dose, Italy 1999–2004.
First dose Second and third dose
N P-d RR adj
1 (95% CI) N P-d RR adj
1 (95% CI)
Any administration of six antigens 30 2457 1.9 (1.0–3.4) 14 1655 1.2 (0.7–2.1)
Hexavalent products
2 18 1263 2.2 (1.1–4.4) 7 965 1.0 (0.5–2.1)
Hexavac 10 580 2.7 (1.1–6.9) 3 480 0.8 (0.3–2.6)
Infanrix hexa 8 668 1.9 (0.8–4.2) 4 485 1.1 (0.5–2.9)
Other concomitant administration of six
antigens
12 1194 1.6 (0.8–3.2) 7 690 1.4 (0.6–3.0)
Control period 192 29875 1 192 29875 1
N: Number of deaths; P-d: Person-days at risk; RR adj: adjusted Rate Ratio; CI: Confidence Interval.
1RRs are estimated by the Poisson regression model and adjusted by age group (31–80; 81–100; 101–120; 121–180; 181–360; 361–729 for the first dose; 31–180; 181–
360; 361–729 for the second-third dose).
2The information on the brand name of the hexavalent product was missing for 1 infant (the event occurred in the control period).
doi:10.1371/journal.pone.0016363.t005
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ering unacceptable even extremely rare adverse effects. An
indirect evidence of the potential benefits associated with the
vaccination coverage is provided by the outbreak of severe diseases
which reappears a consequence of a decrease in the immunisation
coverage. The recent outbreak of a poliomielitis epidemics in
Tajikistan, with hundreds of cases and several deaths, is only the
last in a series of outbreaks of otherwise entirely preventable
diseases [28]. These episodes provide further evidence of the
largely positive benefit-risk profile of extensive immunisation
programmes.
In conclusion, our findings do not confirm the signal raised in
Germany ofa 23 fold increase in the risk ofSUD in association withthe
administration of a hexavalent vaccine. Differently from the German
signal, where the increased risk concerned the forth dose (infants in the
second year of life), in our study only the first dose, which is
administered when the incidence of SUD is greater, appears to carry a
smaller, though statistically significant, increase in the risk of SUD. The
residual uncontrolled confounding effect of age may partly explain this
finding. Given the extremely low mortality rate for SUD in Italy, the
power ofthe study wastoolimited to rule outa small increase in the risk
of death in association with any specific vaccine either during the
second year of life or following the third vaccine dose. At present, even
though many studies investigated the potential association between
vaccinations and the occurrence of SUD, only limited evidence is
relevant to the role of hexavalent vaccines. Further studies conducted
on similar populations may contribute additional evidence and allow a
meta-analysis to obtain more precise estimates.
Nevertheless, our findings are globally reassuring, when
considering that around 4.5 million doses of hexavalent products
were administered in Italy during the study period. They are also
coherent with the limited number of SUDs reported to the Italian
pharmacovigilance system after the conclusion of this study.
During the period 2005–2009, three deaths were reported within
two weeks following the administration of a hexavalent product,
out of around 2.5 million vaccinated infants and 7.5 million doses.
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